Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Curis is a therapeutic drug development company focusing on cancer, neurological, and dermatological diseases. The company utilizes technologies that modulate biological pathways controlling tissue growth and repair. Operations are funded primarily through strategic collaborations (Genentech, Wyeth, Procter & Gamble), license fees, and equity/debt financing. The company has never been profitable and maintains an accumulated deficit of approximately $689.6 million.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 |
|---|---|---|
| Net Revenues | $4,270,439 | $8,867,752 |
| Net Loss | $(1,536,627) | $(9,509,816) |
| Loss Per Share (Basic & Diluted) | $(0.03) | $(0.19) |
| Cash and Cash Equivalents | $21,104,181 | $21,104,181 (Balance Sheet) |
| Marketable Securities | $14,083,181 | $14,083,181 (Balance Sheet) |
| Total Current Assets | $38,966,285 | $38,966,285 (Balance Sheet) |
| Total Current Liabilities | $6,628,366 | $6,628,366 (Balance Sheet) |
| Long-Term Debt (Net of Current) | $1,041,667 | $1,041,667 (Balance Sheet) |
| Net Cash Used in Operating Activities | N/A | $(8,182,656) |
Material Changes vs. Prior Period
- Revenue Surge: Net revenues increased 107% for the three months and 256% for the nine months compared to the prior year periods. This was primarily driven by a $2.28 million license fee revenue recognized from a settlement agreement with Micromet AG regarding a previously written-down note receivable.
- Contra-Revenue Reduction: Contra-revenues (cost reimbursements to Genentech for co-development) decreased significantly ($355k for Q3 vs. $819k prior year; $1.73M for 9 months vs. $5.7M prior year). This reduction occurred because Curis elected to cease participation in the co-development of a basal cell carcinoma drug candidate effective August 31, 2006, shifting full cost responsibility to Genentech.
- Stock-Based Compensation: Expenses increased substantially due to the adoption of SFAS 123(R) on January 1, 2006. Stock-based compensation expense was $968,000 for the three months and $3.0 million for the nine months ended September 30, 2006, compared to negligible amounts in the prior year.
- Investment Write-downs: The company recorded a $164,000 charge for the impairment of its investment in Aegera Therapeutics and a $15,000 loss on the sale of Micromet equity.
Guidance, Outlook, and Risks
- Strategic Shift: Management announced a strategic focus on rapidly developing later-stage drug programs, specifically new proprietary multi-targeted cancer inhibitors, while winding down earlier-stage discovery research (e.g., spinal muscular atrophy).
- Liquidity Outlook: Management believes existing capital resources ($35.2 million in cash and marketable securities) combined with expected collaboration payments should fund operations into the second half of 2008. However, the company expects to incur significant operating losses and will require additional financing in the future.
- Recent Developments:
- Genentech filed an IND for a Hedgehog antagonist in October 2006, triggering a $3.0 million milestone payment to Curis.
- Wyeth extended its research funding agreement through February 2008.
- Curis established a wholly-owned subsidiary in Shanghai, China, requiring a $2.1 million capital contribution by August 2008.
- Risk Factors:
- Restatement Risk: The company restated financial results for 2003-2005 due to accounting errors regarding revenue recognition, which could lead to securities litigation.
- Sublease Default: A subtenant defaulted on the lease for Curis's Cambridge facility in August 2006. Curis has accrued $401,000 for remaining lease obligations through April 2007.
- Financing Needs: Continued profitability is not expected in the foreseeable future; failure to secure additional funding could materially adversely affect operations.
Investor Verification Checklist
- Micromet Settlement Collection: Verify the receipt of the remaining Euro-denominated payments from Micromet (approx. $1.0 million due May 2007) and monitor exchange rate impacts.
- Genentech Milestone Payments: Confirm the receipt of the $3.0 million payment triggered by the October 2006 IND filing and monitor future clinical milestones.
- Sublease Liability: Assess the risk of additional costs related to the vacant Cambridge facility and the inability to sublet the space through April 2007.
- China Subsidiary Funding: Monitor the capitalization of Curis Shanghai and the associated $2.1 million funding requirement, noting that funds are restricted to China.
- Restatement Litigation: Review any ongoing or potential securities class action litigation stemming from the 2003-2005 financial restatement.